PEOPLE - Changes at Abbott Laboratories:
This article was originally published in Clinica
Abbott Laboratories executive vice-president of the $4bn diagnostics division Edward Michael and executive vice-president of $1.1bn vascular medical devices division John Capek are among the group's four directors who will report directly to CEO Miles White following the sudden retirement of group No 2, COO Richard Gonzalez. Abbott is now committed to growing the diagnostics operation, after the recent collapse of GE's proposed $8.13bn takeover, but it has slipped to third in the world rankings, behind Roche and the Dade Behring-enhanced Siemens Medical Solutions Diagnostics.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.